Navigation Links
Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
Date:12/11/2007

the Republic of Ireland.

Efavirenz is marketed by Bristol-Myers Squibb under the tradename SUSTIVA(R) in the United States, Canada and six major countries of the European Union. Efavirenz will continue to be commercialized by Merck & Co, Inc, through its affiliate Merck Sharp & Dohme (MSD) Limited under the tradename STOCRIN(R) in all other countries within the European Union and many countries outside of the United States. Emtricitabine and tenofovir disoproxil fumarate are commercialized by Gilead under the tradenames Emtriva(R) and Viread(R), respectively, and are commonly prescribed together as a once-daily, fixed-dose tablet, marketed under the tradename Truvada(R) for use as part of combination therapy.

ATRIPLA is currently sold in the United States and Canada through a joint venture between Bristol-Myers Squibb and Gilead. ATRIPLA was approved by the U.S. Food and Drug Administration (FDA) in July 2006 and by Health Canada in October 2007. Gilead and Merck previously announced a collaboration to distribute ATRIPLA in developing countries.

Important Product Safety Information (including Boxed WARNINGS) About

ATRIPLA (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil

fumarate 300 mg), Emtriva (emtricitabine), Viread (tenofovir disoproxil

fumarate [DF]) and Truvada (emtricitabine/tenofovir DF) in the United

States Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination with other antiretrovirals.

Emtriva, Viread, Truvada and ATRIPLA are not approved for the treatment of chronic hepatitis B virus (HBV) infection and their safety and efficacy have not been established in patients co-infected with HBV and HIV. Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued Viread or Emtriva, which are components of Truvada and ATRIPLA. In some of these patients t
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Bristol-Myers Squibb, New Jersey Childrens Hospital Launch Center for Immune System Disorders & Infectious Diseases Including HIV/AIDS
2. Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
3. PARIs eFlow Included in Gileads NDA Submission for Aztreonam Lysine for Inhalation
4. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
6. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
7. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
8. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
11. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... , September 12, 2014 ... Market by Application [Beverages (Alcoholic, CSD, Sports & Energy ... Pet Food, Meat & Seafood)], by Material (Aluminum ... by MarketsandMarkets, defines and segments the Food & ... of each application in terms of volumes and ...
(Date:9/12/2014)... , Sept. 12, 2014 /PRNewswire-iReach/ -- 9 th ... 22-24, 2014 – Bethesda, MD ... http://www.fdanews.com/9thInspectionsSummitEarlyBird   Photo - http://photos.prnewswire.com/prnh/20140912/145652 ... for the next inspection than to get a glimpse ... during and after an inspection. Come to ...
(Date:9/12/2014)... 12, 2014 Research and Markets ... "Global Medical Technologies Market 2014-2018" report to ... a collective term for software solutions, medical devices, ... health. The Global Medical Technologies market covers active ... In vitro diagnostics technology, dental technology, electromechanical medical ...
Breaking Medicine Technology:Food & Beverage Metal Cans Market Worth $49.20 Billion by 2019 2Food & Beverage Metal Cans Market Worth $49.20 Billion by 2019 3Food & Beverage Metal Cans Market Worth $49.20 Billion by 2019 4FDAnews Announces: Early Bird Registration Discount Ends Sept.19 for 9th Annual Inspections Summit, Oct. 22-24, 2014 2FDAnews Announces: Early Bird Registration Discount Ends Sept.19 for 9th Annual Inspections Summit, Oct. 22-24, 2014 3Global Medical Technologies Market 2014-2018: Key Vendors are GE, Johnson & Johnson, Medtronic, Roche and Siemens 2Global Medical Technologies Market 2014-2018: Key Vendors are GE, Johnson & Johnson, Medtronic, Roche and Siemens 3
... and CAMPBELL, Calif. , May ... sophisticated risk characterization and personalized therapy guidelines for ... of advanced tests, offering an accompanying nutrition program, ... Director stated:  "With appropriate risk characterization and treatment, ...
... May 25 The U.S. Food and Drug Administration approved Lumizyme (alglucosidase ... a rare genetic disorder. , , ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , , , ... an estimated 1 in every 40,000 to 300,000 births. Its primary symptom is ...
Cached Medicine Technology:Health Network Laboratories (HNL) Enters Into License Agreement With Hunter Laboratories to Provide HunterHeart Cardiovascular Disease Management Program. 2FDA Approves New Treatment for Late-Onset Pompe Disease 2FDA Approves New Treatment for Late-Onset Pompe Disease 3
(Date:9/15/2014)... (PRWEB) September 15, 2014 (PRWEB) September 15, 2014 ... not; what the startup business requirements are in each ... new business. , Speakers include industry professionals, such as ... Center in Oakland,CA and cannabis business consultant ... who are already successfully running legal marijuana businesses all ...
(Date:9/14/2014)... Petersburg, FL (PRWEB) September 15, 2014 Skin ... external factors like sun damage and not moisturizing properly. However, ... if skin has been cared for. , Two main reasons ... 2) Loss of hyaluronic acid in the skin , During ... and both of these are responsible for important moisture retention ...
(Date:9/14/2014)... Government support for safe patient handling has ... market , The global patient handling equipment market ... five years. The growth of this market is ... increasing lifestyle diseases such as diabetes and Cardiovascular ... market is driven by factors such as government ...
(Date:9/14/2014)... (HealthDay News) -- Getting enough sleep each night may mean you,re ... a new study suggests. The study included more than 3,700 ... an average of seven years. Those who slept less than ... more likely to have extended absences from work due to illness, ... off from work due to sickness were those who slept between ...
(Date:9/14/2014)... A new DePuy Pinnacle hip lawsuit has been filed by ... Franklin County, Ohio man who underwent hip surgery to remove ... filed against Johnson & Johnson and its subsidiary, DePuy Orthopedics, ... when the Pinnacle Hip device was surgically implanted in his ... hip implant lawsuit , the man underwent a revision surgery ...
Breaking Medicine News(10 mins):Health News:How to Start And Run a Successful Legal Marijuana Business 2Health News:2 Reasons Skin Becomes Dryer with Age and What To Do About It, From Sublime Beauty® 2Health News:2 Reasons Skin Becomes Dryer with Age and What To Do About It, From Sublime Beauty® 3Health News:10.7% CAGR For Patient Handling Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:10.7% CAGR For Patient Handling Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:10.7% CAGR For Patient Handling Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:A Good Night's Sleep May Mean a Good Day's Work 2Health News:Wright & Schulte LLC Files Another DePuy Pinnacle Hip Lawsuit Purporteding Risky Revision Surgery Needed Due To Failure of Metal-on-Metal Hip Replacement 2Health News:Wright & Schulte LLC Files Another DePuy Pinnacle Hip Lawsuit Purporteding Risky Revision Surgery Needed Due To Failure of Metal-on-Metal Hip Replacement 3Health News:Wright & Schulte LLC Files Another DePuy Pinnacle Hip Lawsuit Purporteding Risky Revision Surgery Needed Due To Failure of Metal-on-Metal Hip Replacement 4Health News:Wright & Schulte LLC Files Another DePuy Pinnacle Hip Lawsuit Purporteding Risky Revision Surgery Needed Due To Failure of Metal-on-Metal Hip Replacement 5
... WHAT: 211 San Diego executives will highlight key initiatives the, ... nationwide service, discuss the ... times of need, and honor community leaders for their support and, ... Journey event. 211 San Diego also will, ...
... 11 The Ensign Group, Inc. (Nasdaq: ... Ensign(TM) group of skilled nursing, rehabilitative care services ... will participate in the Eighth Annual JMP Securities ... Ritz-Carlton in San Francisco. (Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO )Christopher ...
... Reiterates Going Concern Opinion to Comply with NASDAQ ... Encorium Group, Inc. (Nasdaq: ENCO ... (CRO) that provides design, development, and management capabilities ... of the world,s leading pharmaceutical companies, today announced ...
... - The Westaim Corporation announced today that for the quarter ended ... or 3 cents per share, on revenues of $5.2 million compared ... share, on revenues of $5.2 million in the previous year. The ... was $2.3 million compared to income of $3.2 million for the ...
... This release is available in French . ... immunity, men may not have been dealt an equal hand. ... Institute of the McGill University Health Centre and McGill University, ... men. In fact, the production of estrogen by females could ...
... Trust Incorporated (NYSE: HR ) today announced its ... 2009. This dividend, in the amount of $0.385 per ... record on May 22, 2009. The total dividend of ... operations determined in accordance with GAAP. The Company,s cash ...
Cached Medicine News:Health News:211 San Diego Provides Support to San Diegans in Times of Crisis 2Health News:The Ensign Group to Present at the Eighth Annual JMP Securities Research Conference on May 19th 2Health News:The Ensign Group to Present at the Eighth Annual JMP Securities Research Conference on May 19th 3Health News:Encorium Group Enters into Non-Binding Letters of Intent 2Health News:Encorium Group Enters into Non-Binding Letters of Intent 3Health News:Encorium Group Enters into Non-Binding Letters of Intent 4Health News:Encorium Group Enters into Non-Binding Letters of Intent 5Health News:Westaim announces 2009 first quarter results 2Health News:Westaim announces 2009 first quarter results 3Health News:Equality of the sexes? Not always when it comes to biology 2Health News:Healthcare Realty Trust Announces First Quarter Dividend 2Health News:Healthcare Realty Trust Announces First Quarter Dividend 3Health News:Healthcare Realty Trust Announces First Quarter Dividend 4
Free Estriol (E3) RIA Reproductive Hormones 024-IDC-2000...
Prolactin EIA Reproductive Markers 025-BC-1037...
... (17aOHP) is produced by both the ... has relatively little progestational activity, it ... it is the,immediate precursor to 11-desoxycortisol ... 21-hydroxylation of 17aOHP,measurement of 17aOHP is ...
FSH EIA Reproductive Markers 025-BC-1029 Follicle Stimulating Hormone...
Medicine Products: